New precision heart ablation trial pulled before it began
NCT ID NCT06701292
First seen Jan 31, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This pilot study aimed to test a new, more targeted ablation technique for atrial fibrillation using advanced mapping technology. The goal was to see if it could shorten procedure time and reduce the number of burns needed compared to the standard approach. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiofrequency ablation guided by omnipolar mapping technology
What this could lead to
If successful, this technique could make ablation faster and more precise, potentially improving outcomes for people with atrial fibrillation.
What could go wrong
The study was withdrawn before any participants were enrolled, so no data is available. It is unclear if the approach offers real benefits over standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.